Prevalence of statin-drug interactions in older people: A systematic review

European Journal of Clinical Pharmacology

Volumn 72, Issue 5, 2016, Pages 513-521

  Thai, Michele ^a   Reeve, Emily ^b,c,e   Hilmer, Sarah N ^b,c   Qi, Katie ^a   Pearson, Sallie Anne ^a,d,e   Gnjidic, Danijela ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Drug drug interactions; Older people; Prevalence; Statins

Indexed keywords

AMIODARONE; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CLARITHROMYCIN; CYCLOSPORIN; DILTIAZEM; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; MACROLIDE; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; WARFARIN;

AGED; DRUG EFFECT; GERIATRIC PATIENT; HUMAN; POLYPHARMACY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; DRUG INTERACTION;

AGED; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PREVALENCE;

EID: 84954469051     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-016-2011-7     Document Type: Review

References (47)

1. Morgan TK, Williamson M, Pirotta M, Stewart K, Myers SP, Barnes J (2012) A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust 196:50-53
2. Elliott RA (2006) Problems with medication use in the elderly: an Australian perspective. J Pharm Pract 36:58-66
3. Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C (2013) Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother 47:324-332
4. Johnell K, Klarin I (2007) The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 30:911-918
5. Gnjidic D, Johnell K (2013) Clinical implications from drug-drug and drug-disease interactions in older people. Clin Exp Pharmacol Physiol 40:320-325
6. Hilmer SN, McLachlan AJ, Le Couteur DG (2007) Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 21:217-230
7. Hines LE, Murphy JE (2011) Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother 9:364-377
8. Wallach Kildemoes H, Vass M, Hendriksen C, Andersen M (2012) Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour. Health Policy 108:216-227
9. Lo-Ciganic WH, Boudreau RM, Gray SL et al (2013) Changes in cholesterol-lowering medications use over a decade in community-dwelling older adults. Ann Pharmacother 47:984-992
10. Gnjidic D, Le Couteur DG, Blyth FM et al (2013) Statin use and clinical outcomes in older men: a prospective population-based study. BMJ Open 3(3):e002333
11. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ (2008) Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol 51:37-45
12. Roberts CG, Guallar E, Rodriguez A (2007) Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci 62:879-887
13. Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278
14. Bellosta S, Corsini A (2012) Statin drug interactions and related adverse reactions. Expert Opin Drug Saf 11:933-946
15. Ho CKM, Walker SW (2011) Statins and their interactions with other lipid-modifying medications: safety issues in the elderly. Ther Adv Drug Saf 3:35-46
16. Bottorff MB (2006) Statin safety and drug interactions: clinical implications. Am J Cardiol 97:27C-31C
17. Corsini A, Ceska R (2011) Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? Curr Med Res Opin 27:1551-1562
18. Cabrera MA, Dip RM, Furlan MO, Rodrigues SL (2009) Use of drugs that act on the cytochrome P450 system in the elderly. Clinics (Sao Paulo, Brazil) 64:273-278
19. Bakhai A, Rigney U, Hollis S, Emmas C (2012) Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf 21:485-493
20. Ming EE, Davidson MH, Gandhi SK et al (2008) Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol 2:453-463
21. Piacentini N, Trifiro G, Tari M, Moretti S, Arcoraci V, group U (2005) Statin-macrolide interaction risk: a population-based study throughout a general practice database. Eur J Clin Pharmacol 61:615-620
22. Einarson TR, Metge CJ, Iskedjian M, Mukherjee J (2002) An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme a reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther 24:2126-2136
23. Egger SS, Ratz Bravo AE, Hess L, Schlienger RG, Krahenbuhl S (2007) Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 24:429-440
24. Karimi S, Hough A, Beckey C, Parra D (2010) Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center. J Manag Care Pharm 16:472-481
25. Petropoulos JB, Bello-Quintero CE (2004) Frequency of simvastatin prescriptions with potentially interacting medications in a Veterans Affairs health care system. J Manag Care Pharm 10:239-243
26. Bacic-Vrca V, Marusic S, Erdeljic V, Falamic S, Gojo-Tomic N, Rahelic D (2010) The incidence of potential drug-drug interactions in elderly patients with arterial hypertension. Pharm World Sci 32:815-821
27. Ghibelli S, Marengoni A, Djade CD et al (2013) Prevention of inappropriate prescribing in hospitalized older patients using a computerized prescription support system (intercheck registered trademark). Drugs Aging 30:821-828
28. Halvorsen KH, Granas AG, Engeland A, Ruths S (2012) Prescribing quality for older people in Norwegian nursing homes and home nursing services using multidose dispensed drugs. Pharmacoepidemiol Drug Saf 21:929-936
29. Kerr KP, Mate KE, Magin PJ et al (2014) The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians. J Clin Pharm Ther 39:383-389
30. Lao CK, Ho SC, Chan KK, Tou CF, Tong HHY, Chan A (2013) Potentially inappropriate prescribing and drug-drug interactions among elderly Chinese nursing home residents in Macao. Int J Clin Pharm 35:805-812
31. Lea M, Rognan SE, Koristovic R, Wyller TB, Molden E (2013) Severity and management of drug-drug interactions in acute geriatric patients. Drugs Aging 30:721-727
32. Marcum ZA, Driessen J, Thorpe CT, Gellad WF, Donohue JM (2014) Effect of multiple pharmacy use on medication adherence and drug-drug interactions in older adults with medicare part D. J Am Geriatr Soc 62:244-252
33. Pasina L, Djade CD, Nobili A et al (2013) Drug-drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiol Drug Saf 22:1054-1060
34. Popovic B, Quadranti NR, Matanovic SM et al (2014) Potentially inappropriate prescribing in elderly outpatients in Croatia. Eur J Clin Pharmacol 70:737-744
35. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST (2008) Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300:2867-2878
36. Roughead EE, Kalisch LM, Barratt JD, Gilbert AL (2010) Prevalence of potentially hazardous drug interactions amongst Australian veterans. Br J Clin Pharmacol 70:252-257
37. Dudash K, Negri G, Baccarini S, Rabinowitz C, Maio V (2011) Prevalence and predictors of potentially significant drug-drug interactions in the elderly. Value Health 14:A7
38. Espinosa-Bosch M, Santos-Ramos B, Gil-Navarro MV, Santos-Rubio MD, Marin-Gil R, Villacorta-Linaza P (2012) Prevalence of drug interactions in hospital healthcare. Int J Clin Pharm 34:807-817
39. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH (2007) Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 16:641-651
40. Hassan FA, Taylor DM, Leow FHP, Doolan G, Knott JC (2006) Potential interactions between drugs taken by emergency department patients of an Australian hospital. J Pharm Pract 36:266-270
41. Florentin M, Elisaf MS (2012) Simvastatin interactions with other drugs. Expert Opin Drug Saf 11:439-444
42. Neuvonen PJ, Niemi M, Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565-581
43. Ronaldson KJ, O'Shea JM, Boyd IW (2006) Risk factors for rhabdomyolysis with simvastatin and atorvastatin. Drug Saf 29:1061-1067
44. Vitry AI (2007) Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 63:709-714
45. Vonbach P, Dubied A, Krahenbuhl S, Beer JH (2008) Evaluation of frequently used drug interaction screening programs. Pharm World Sci 30:367-374
46. Saito M, Hirata-Koizumi M, Urano T, Miyake S, Hasegawa R (2005) A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J Clin Pharm Ther 30:21-37
47. Thai M, Hilmer S, Pearson SA, Reeve E, Gnjidic D (2015) Prevalence of potential and clinically relevant statin-drug interactions in frail and robust older inpatients. Drugs Aging 32:849-856